



Disclosure of a transparency notification

(Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings)

Mechelen, Belgium, 2 June 2017 – Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market (the 'Belgian Transparency Act'), that it received a transparency notification dated 1 June 2017 (the 'Notification'), indicating that Rudi Pauwels (through entities controlled by him) now holds 1.4% (rounded) of the voting rights in Biocartis. As a result, the lowest notification threshold of 3% has been crossed.

The Notification contains the following information:

- **Reason for the Notification:** downward crossing of the lowest threshold.
- **Notification by:** a parent undertaking or a controlling person.
- **Persons subject to the notification requirement:** Rudi Pauwels; Benaruca S.A., 4 rue du Fort Wallis, 2714 Luxembourg; Benaruca Life Science Investments S.à r.l., 4 rue du Fort Wallis, 2714 Luxembourg.
- **Transaction date:** 31 May 2017.
- **Threshold that is crossed:** 3%.
- **Denominator:** 44,648,105.
- **Details of the Notification:** Benaruca S.A. holds 27,930 voting securities, Benaruca Life Science Investments S.à r.l. holds 614,523 voting securities.
- **Chain of controlled undertakings through which the holding is effectively held:** Rudi Pauwels controls Benaruca S.A., which in turn controls Benaruca Life Science Investments S.à r.l.
- **Additional information:** Benaruca Life Science Investments S.à r.l. was incorporated on 30 May 2017. On such date, Benaruca S.A. contributed 2,479,808 shares of Biocartis Group NV into Benaruca Life Science Investments S.à r.l.

The Notification is available [here](#) on the website of the Company.

Pursuant to the Belgian Transparency Act and the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority ('FSMA') is required by all natural and legal persons in each case where the percentage of voting rights in the Company held by such persons reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company.

----- END -----

More information:

Renate Degrave

Manager Corporate Communications & Investor Relations

e-mail rdegrave@biocartis.com

tel +32 15 631 729

mobile +32 471 53 60 64

[@Biocartis](https://twitter.com/Biocartis)

www.linkedin.com/Biocartis

About Biocartis

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla™ platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis offers nine oncology tests and two infectious disease tests. More information: www.biocartis.com. Press Photo Library available [here](#). Follow us on [@Biocartis_](https://twitter.com/Biocartis_).

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.